Synapse - Genitourinary Oncology Service

Results (5694)

MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions

Journal Article

Sato, H.; Schoenfeld, A. J.; Siau, E.; Lu, Y. C.; Tai, H.; Suzawa, K.; Kubota, D.; Lui, A. J. W.; Qeriqi, B.; Mattar, M.; more...
Clinical Cancer Research (2020)

Fulltext@MSK | Save

Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations

Journal Article

Mota, J. M.; Barnett, E.; Nauseef, J. T.; Nguyen, B.; Stopsack, K. H.; Wibmer, A.; Flynn, J. R.; Heller, G.; Danila, D. C.; Rathkopf, D.; more...
JCO Precision Oncology (2020)

Fulltext@MSK | Save

Immune checkpoint blockade for prostate cancer: Niche role or next breakthrough?

Review

Vargas P. de Almeida, D.; Fong, L.; Rettig, M. B.; Autio, K. A.
American Society of Clinical Oncology Educational Book (2020)

Fulltext@MSK | Save

Radiographic predictors of pathologic response to neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with high-grade upper tract urothelial carcinoma

Meeting Abstract

Wong, N. C.; Ghafoor, S.; Vargas, H. A.; Bajorin, D. F.; Coleman, J.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer

Meeting Abstract

Yoshikawa, Y.; Wang, X. V.; Chen, Y. H.; Mazzu, Y. Z.; Chakraborty, G.; Jehane, L. E.; Rajanala, S. H.; Hirani, R.; Nandakumar, S.; Stopsack, K. H.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)

Meeting Abstract

Zhang, T.; Ballman, K. V.; Choudhury, A. D.; Chen, R. C.; Watt, C.; Wen, Y.; Zemla, T.; Emamekhoo, H.; Vaishampayan, U. N.; Morris, M. J.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)

Meeting Abstract

Tannir, N. M.; McDermott, D. F.; Escudier, B.; Hammers, H. J.; Aren, O. R.; Plimack, E. R.; Barthelemy, P.; Neiman, V.; George, S.; Porta, C.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)

Meeting Abstract

Taplin, M. E.; Gleave, M.; Evans, C. P.; Efstathiou, E.; Kantoff, P. W.; Ross, A.; Shore, N. D.; Briganti, A.; Hadaschik, B. A.; Heidenreich, A.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Tran, B.; Horvath, L.; Dorff, T. B.; Greil, R.; Machiels, J. P. H.; Roncolato, F.; Autio, K. A.; Rettig, M.; Fizazi, K.; Lolkema, M. P.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101

Meeting Abstract

Voss, M. H.; Motzer, R. J.; Albiges, L.; Rini, B. I.; Schmidinger, M.; Larkin, J. M. G.; Haanen, J. B. A. G.; Kollmannsberger, C. K.; Campbell, M. T.; Grimm, M. O.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save